Goldman Sachs Group Cuts Stake in Puma Biotechnology (PBYI)
PBYI Insider Trading Activity - Puma Biotechnology, Inc.
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Puma Biotechnology, Inc. | LinkedIn
PUMA BIOTECHNOLOGY, INC. : PBYI Stock Price | US74587V1070 | MarketScreener
Puma Biotechnology Surging
Why Puma Biotechnology, Inc. Stock Crashed 37% in March | Fox Business
Puma Biotechnology (PBYI) - 5 Price Charts 2012-2023 (History)
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
Federal Jury Awards Puma Biotechnology Investors Damages in Securities Class-Action Verdict - Los Angeles Business Journal
Should You Be Worried About Insider Transactions At Puma Biotechnology, Inc. (NASDAQ:PBYI)?
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology | Business Wire
Articles about Puma Biotechnology
Puma Biotechnology - Crunchbase Company Profile & Funding
Puma Biotechnology Third Quarter 2022 Earnings: Beats Expectations
Should You Buy Puma Biotechnology Inc (PBYI) Stock After it Has Gained 6.09% in a Week?
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Puma Biotechnology, Inc. 2022 Q4 - Results - Earnings Call Presentation (NASDAQ:PBYI) | Seeking Alpha
Former Puma Biotechnology Executive Sentenced to More than Two Years in Prison for Insider Trading | BioSpace
Exhibitor Puma Biotechnology 07-10 - Scripps CME Connection
PumaBiotech (@pumabiotech) / Twitter
Puma Biotechnology
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
